- Business
- Know Labs, Inc. (NYSE American: KNW) develops and commercializes proprietary non-invasive medical diagnostic technologies based on radiofrequency (RF) dielectric spectroscopy and Bio-RFID platforms that use radio waves and electromagnetic energy to identify, measure, and analyze molecular signatures of organic and inorganic materials in real-time; its core products include the KnowU wearable continuous glucose monitor (CGM) for pain-free blood glucose tracking via adhesive or strap attachment, a companion mobile app for real-time readings and trend analysis, and a form-factor-agnostic technology applicable to over 100 diagnostic uses such as oxygen, alcohol, and metabolized drugs, with potential extensions to industrial sectors like food, agriculture, and security. Founded in 1998 and headquartered in Seattle, Washington, the company targets diabetes management for over 550 million global patients with Type 1 and Type 2 diabetes plus prediabetes, alongside broader health monitoring markets, while operating principally in the United States through medical-grade devices advancing toward FDA clearance via ongoing clinical trials, hardware development, algorithm refinement, and a portfolio of more than 270 patents worldwide. In August 2025, Goldeneye 1995 LLC, an affiliate of fintech investor Greg Kidd, completed a $125 million strategic acquisition of controlling interest through 1,000 Bitcoin and $15 million cash contributions for 357.8 million new shares, triggering leadership changes with Kidd assuming roles as chief executive officer and chairman, new executives including Kirk Chapman as COO and Kitty Payne as CFO, founder Ron Erickson transitioning to president of a retained diagnostics division and lead director, a corporate rebranding to USBC, Inc. with ticker change to USBC effective August 15, 2025, and a pivot to multi-disciplinary operations incorporating Bitcoin yield-generation treasury strategies, USBC token development as a redeemable high-yield digital dollar on blockchain with digital identity features, and sustained investment in non-invasive health innovations.